GSK PLC
(NYSE:GSK)
$
34.08
-0.04 (-0.12%)
Market Cap: 69.61 Bil
Enterprise Value: 84.95 Bil
PE Ratio: 21.96
PB Ratio: 3.90
GF Score: 71/100 GlaxoSmithKline PLC at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 04:10PM GMT
Release Date Price:
$40.57
(-1.79%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning, and welcome once again. We are here with the top management of GlaxoSmithKline at Cowen's 42nd Annual Healthcare Conference. We're very, very pleased to have with us Dr. Hal Barron, who is Chief Scientific Officer and President of Research and Development. Dr. Barron has shown over the last 30 or so years that he's clearly one of the industry's most prolific drug development experts. So it's always great to have conversations with him.
Questions & Answers
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
So Hal, thanks again for your time this morning. I'd like to start out and ask, what have -- do you believe, have been your greatest accomplishments in R&D since joining GSK a little over 4 years ago?
Hal V. Barron
GlaxoSmithKline plc - Chief Scientific Officer, President of R&D and Director
Yes. Thanks, Steve. Thanks for having me. I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot